Press Releases July 22, 2026 07:00 AM

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

Chief Medical Officer of OKYO Pharma Purchases 20,000 Shares at $1.40, Demonstrating Confidence Ahead of Phase 3 Trial

By Marcus Reed OKYO

OKYO Pharma's Chief Medical Officer, Dr. Flavio Mantelli, has purchased 20,000 shares of the company at $1.40 per share. This insider buying occurs as the company prepares to initiate a global Phase 3 clinical trial for urcosimod, targeting neuropathic corneal pain. The move signals confidence in the upcoming pivotal study and the company’s therapeutic prospects.

OKYO

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Insider buying by the Chief Medical Officer signals confidence in company prospects.
OKYO plans to start a global Phase 3 clinical trial for urcosimod in H2 2026 targeting neuropathic corneal pain.
Focus on innovative treatments for eye diseases could impact biotechnology and healthcare sectors.

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company’s ordinary shares on NASDAQ at $1.40 per share.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

Risks

Clinical trial enrollment challenges or failures could negatively impact development progress and stock value.
Regulatory approvals remain uncertain and can affect drug commercialization timelines.
Market competition in ophthalmic therapies could impact OKYO's market share and revenue potential.

Menu

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

Key Points

Risks

More from Press Releases